AMGN Add to watchlist $336.79 +0.31 (+0.09%) Last updated: May 31, 2026 03:57
52-Week Range
$336.79
$267.83 $336.79 $391.29

Fundamentals Overview

Amgen Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 23.5 PEG 0.75 P/B 19.79 P/S 4.88

Intrinsic value (DCF)

+210.7% upside vs price

Profitability

Net margin 20.9%

Risk (Beta)

0.44 — lower vol

Earnings & growth

EPS $14.34 Rev -12.9% Profit +36.5% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 56% confidence Risk: Lower Volatility — Beta 0.44. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +210.7% upside vs price · Analyst grade: B+

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -21.5% · 3M vs Healthcare sector: -7.1%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$181.77B
P/E (TTM)
23.49
EPS (TTM)
$14.34
Dividend Yield
2.91%
52-Week Range
$267.83 - $391.29
Volume vs Avg
N/A
Beta
0.44

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-rel...
Sector: Healthcare
Headquarters: US
Employees: 28,000
IPO Date: Jun 1983
Website: www.amgen.com
Beta: 0.44 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 3, Equal Weight: 6, Hold: 4, Market Perform: 1, Neutral: 7, Outperform: 3, Overweight: 5, Underperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $1,046.40; current price is $336.79. That’s a +210.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 23.49
DCF value (model) $1,046.40 (210.7% upside)
PEG (TTM) 0.75
P/B (TTM) 19.79
P/S (TTM) 4.88
P/FCF (TTM) 21.14
Liquidity & enterprise
Current Ratio (TTM) 1.26
Quick Ratio (TTM) 1.01
Cash Ratio (TTM) 0.48
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 20.95%
Gross margin (TTM) 71.46%
Operating margin (TTM) 31.63%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for AMGN.

Analyst Sentiment at a Glance

B+ Sentiment Weakening
Buy 3Equal Weight 6Hold 4Market Perform 1Neutral 7Outperform 3Overweight 5Underperform 1
0 upgrades, 2 downgrades
Price Target Consensus
Current $336.79
Median $357.50
Consensus $352.00
Low consensus $185.00
High consensus $427.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Piper Sandler maintain Overweight Overweight 2026-05-14
Guggenheim maintain Neutral Neutral 2026-05-04
Truist Securities maintain Hold Hold 2026-05-01
UBS maintain Buy Buy 2026-04-13
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
Guggenheim maintain Neutral Neutral 2026-04-09
Cantor Fitzgerald maintain Neutral Neutral 2026-04-08
Wells Fargo maintain Equal Weight Equal Weight 2026-02-19
Piper Sandler maintain Overweight Overweight 2026-02-18
Freedom Broker downgrade Buy Hold 2026-02-12
Argus Research maintain Buy Buy 2026-02-06
Guggenheim maintain Neutral Neutral 2026-02-06
Cantor Fitzgerald maintain Neutral Neutral 2026-02-04
Leerink Partners maintain Outperform Outperform 2026-02-04
Citigroup maintain Neutral Neutral 2026-02-04
Morgan Stanley maintain Equal Weight Equal Weight 2026-02-04
UBS maintain Buy Buy 2026-01-26
Bernstein downgrade Outperform Market Perform 2026-01-20
Truist Securities maintain Hold Hold 2026-01-08
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Wells Fargo maintain Equal Weight Equal Weight 2025-12-10
BMO Capital maintain Outperform Outperform 2025-12-03
Leerink Partners maintain Outperform Outperform 2025-11-27
Piper Sandler maintain Overweight Overweight 2025-11-14
Freedom Broker maintain Hold Hold 2025-11-12
Cantor Fitzgerald maintain Neutral Neutral 2025-11-06
Wells Fargo maintain Overweight Overweight 2025-11-05
Morgan Stanley maintain Equal Weight Equal Weight 2025-11-05
B of A Securities maintain Underperform Underperform 2025-09-26
Piper Sandler maintain Overweight Overweight 2025-08-25